Short-Term Debt to Equity Ratio: Pasithea Therapeutics Corp. (KTTA)
The current market value of Pasithea Therapeutics (KTTA) shown on this chart reflects the dynamics of a company whose research depends on the stable import of rare reagents and international cooperation. Human capital is secured by the loyalty of leading neurobiologists, which eliminates the risk of losing expertise. The indicator stands at 0.00. The business focuses on the therapy of mental disorders; therefore, project success is determined by clinical achievements rather than market cycles.
Pasithea - analytical breakdowns and key metrics (KTTA)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Pasithea Therapeutics|KTTA - Long-Term Liabilities to Equity|Short-Term Debt to Capital Pasithea Therapeutics|KTTA - Company Aggregate Debts|Debt to Book Capitalization Ratio Pasithea Therapeutics Corp|KTTA - Long-Term Debt Volume|Company Short-Term Debts Pasithea Therapeutics|Quick Liquidity Indicator pasitheaclinics.com
- company profitability and valuation multiples indicators:
Comprehensive company analysis:KTTA Pasithea Therapeutics Corp.
To assess the credit quality of Pasithea Therapeutics (KTTA), the analyst utilizes the short-term debt-to-equity ratio, which compares liabilities maturing within one year against the company's own funds to identify liquidity risks associated with financing the development of the PAS-004 drug and AI projects, where a low level of this metric confirms the biotech startup's financial stability ahead of potential M&A transactions.
Main competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|denalitherapeutics.com - Current Liabilities to Equity|Short-Term Debt to Capital HRMY|Short-Term Debt to Capital Biohaven Ltd (BHVN)|Short-Term Debt to Equity Amylyx AMLX|Short-Term Debt to Capital Coefficient Trevi Corp (TRVI)|Praxis Precision Medicines - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient anavex.com AVXL|CBLL (CeriBell) - Short-Term Debt to Equity Ratio|PRTA: Short-Term Loans to Capital Ratio|ALEC (Alector Inc.) - Short-Term Debt to Capital|ANNX: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital OMER|NGNE - Current Liabilities to Capital|Short-Term Debt to Capital ACIU (AC Immune SA)|Short-Term Debt to Capital Voyager Therapeutics Inc VYGR|NMRA: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN (Tevogen Bio Holdings) - Short-Term Debt to Equity Ratio|ACOG: Short-Term Loans to Capital Ratio|CGTX (Cognition Therapeutics, Inc.) - Short-Term Debt to Capital|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital SAVA|ASRT - Current Liabilities to Capital|Short-Term Debt to Equity Coya Therapeutics COYA|Ratio of Short-Term Indebtedness to Capital VTGN|Ovid Rx - Short-Term Debt to Capital|ABOS - Short-Term Debt to Capital|CervoMed Inc (CRVO) - Short-Term Debt to Equity|Current Liabilities to Equity ATHE (Alterity Therapeutics Limited)|CLNN (Clene Inc) - Short-Term Debt to Capital|Current Liabilities to Capital PepGen Corp PEPG|Short-Term Debt to Equity Ratio JUNS (Jupiter Neurosciences)|Short-Term Debt to Capital Relmada Therapeutics Inc (RLMD)|Annovis Bio Corp - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio GRCE (Grace Therapeutics Inc)|Firefly Neuroscience, Inc - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Klotho Neurosciences Inc KLTO|NRSN: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Reviva Pharmaceuticals Holdings Inc.|Short-Term Debt to Equity MetaVia Inc.|NeurAxis Inc (NRXS) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Helius Medical (HSDT)|Short-Term Debt to Capital passagebio.com (PASG)|Neuphoria Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio NERV (Minerva Neurosciences Inc)|ATHA: Short-Term Debt to Equity Ratio|Addex - Short-Term Loans to Capital Ratio|ALZN: Short-Term Debt to Capital|Cyclerion Therapeutics, Inc. (CYCN) - Short-Term Debt to Capital|Short-Term Debt to Equity Protagenic Therapeutics Inc.|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Capital ATXI|BCLI - Current Liabilities to Capital|Cara Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital chromocell.com CHRO|ELYM - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ITCI (Intra-Cellular Therapies)|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Current Liabilities to Capital Marinus Pharma (MRNS)|Short-Term Debt to Equity NKGen Biotech, Inc.|neurobopharma.com - Current Liabilities to Equity|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Synaptogenix Inc. (SNPX)|Short-Term Debt to Equity Trevena, Inc TRVN|Short-Term Debt to Capital Coefficient Vigil Neuroscience Inc. (VIGL)|Anew Medical, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient cerevel.com CERE